Source: Lieyun Network
Recently, Shanghai Enke Cell Technology Co., Ltd. (referred to as Enke Saiyao) announced the completion of nearly 100 million yuan in A+++ round financing, participated by Pudong Venture Capital and Xingbo Shenghui.
It is reported that the funds from this round of financing will be used to advance clinical trials of core products and the development of new product pipelines, accelerating the clinical translation of NK cell drugs.
Enka Cell is an innovative technology developer in the field of immunocyte therapy. The company focuses on researching and developing innovative immunocyte treatment technologies, specializing in the R&D and production of innovative cell-based drug technologies using NK cells as a foundation. It possesses a unique allogeneic peripheral blood NK cell expansion and cryopreservation platform, gene modification capabilities, and a clinical "off-the-shelf" level ABCDE-NK® strategic platform. Through synthetic immunology strategies such as logic gate genetic circuits, it achieves intelligent editing of NK cells. With the core business of developing NK cell-based drugs, the company has formed a distinctive portfolio. Its main development projects include four major categories with twelve series of technologies and products.